January 22, 2025

Experience the Energy: WuXi Global Forum Recap

The 13th annual WuXi Global Forum, held during J.P. Morgan week, brought together thousands of leaders, innovators, and visionaries from around the world to share ideas and spark meaningful collaborations. This short recap video captures the essence of the event, highlighting key moments that define the spirit of our industry: bold thinking, transformative science, and an unwavering commitment to advancing patient care.

From the Opening Plenary on the “State of Innovation” to over 120 Executive Roundtables led by C-suite leaders, this year’s forum embraced a bold new format designed to foster deeper connections and impactful discussions. The collaborative energy, insightful dialogues, and shared dedication to shaping a healthier future are all reflected in this video.

Join us in celebrating the progress we’ve made and the shared journey that unites us all in transforming patients’ lives.

EVENTS

WuXi Executive Breakfast in Basel: The Most Important Innovation in Drug R&D May Be How the Industry Works Together

Reflections from the WuXi Executive Breakfast at Swiss Biotech Day

May 11, 2026

READ MORE

FEATURED

Reflection on the First Approved PROTAC and the Future of Small Molecule Drugs: A Conversation with Prof. Craig Crews, Yale University

In May 2026, the FDA approved the first PROTAC therapy, marking the arrival of an entirely new class of medicines built on a once-radical idea: instead of merely inhibiting disease-causing proteins, drugs could be designed to eliminate them altogether. At the center of that story is Prof. Craig Crews, whose laboratory at Yale University helped pioneer the PROTAC (PROteolysis TArgeting Chimera) approach more than two decades ago.

June 8, 2026

Many years later, staring at five kilograms of pale drug powder sealed inside a plastic bag, Craig Crews remembered that afternoon in the late 1990s, when almost nobody stopped to see his poster.

June 8, 2026

Across complex therapeutic areas, innovators are applying an expanding range of new modalities, from antibody-drug conjugates (ADCs) and bispecific antibodies to peptides, oligonucleotides, and other advanced formats. Yet as the therapeutic toolbox expands, one principle remains central: modality should follow biology...

May 28, 2026

READ MORE